Zobrazeno 1 - 10 of 99 pro vyhledávání: '"Menakuru S"'
1
Akademický článek
Accuracy of Fecal Polymerase Chain Reaction Testing in Clarithromycin-Resistant Helicobacter Pylori: A Systematic Review and Meta-Analysis.
Autor: Al Qady A; Indiana University School of Medicine, Muncie, IN., Aldhaleei W; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL., Salih M; Faculty of Medicine, Cairo University, Cairo, Egypt., Ali M; Indiana University School of Medicine, Muncie, IN., Menakuru S; Indiana University School of Medicine, Muncie, IN., Nayar KD; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL., Wang Z; Health Care Policy and Research, Mayo Clinic, Rochester, MN., Stancampiano FF; Department of Medicine, Mayo Clinic, Jacksonville, FL., Harris D; Department of Medicine, Mayo Clinic, Jacksonville, FL., Bi Y; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.
Publikováno v: Clinical and translational gastroenterology [Clin Transl Gastroenterol] 2024 Dec 02. Date of Electronic Publication: 2024 Dec 02.
Zobrazit plný text záznamu
2
Akademický článek
Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects.
Autor: Lindmark B; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Li XQ; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Bhattacharya C; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Housler G; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Heijer M; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Bragg RA; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Gränfors M; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Pelay-Gimeno M; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Vaes WHJ; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Menakuru S; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Pizzato PE; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Ericsson H; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.)., Johansson S; Drug Metabolism and Pharmacokinetics, Early Research and Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.L., X.-Q.L.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (C.B.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland (G.H.); Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden(M.H., H.E., S.J.); Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.A.B.); Early Product Development and Manufacture, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.G.); Quotient Sciences, Nottingham, United Kingdom (S.M.); Early Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (P.E.P.); and TNO, Leiden, Netherlands (M.P.-G., W.H.J.V.) susanne.a.johansson@astrazeneca.com.
Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Aug; Vol. 51 (8), pp. 995-1004. Date of Electronic Publication: 2023 Jul 05.
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Report
Unilateral Erosive Arthritis Following Moderna COVID-19 Vaccination.
Autor: Emran J; Internal Medicine, Indiana University Health Ball Memorial Hospital, Muncie, USA., Menakuru S; Internal Medicine, Indiana University Health Ball Memorial Hospital, Muncie, USA., Khan I; Internal Medicine, Indiana University Health Ball Memorial Hospital, Muncie, USA., Dhillon VS; Internal Medicine, Indiana University Health Ball Memorial Hospital, Muncie, USA., Afroz S; Rheumatology, Indiana University Health Ball Memorial Physicians Rheumatology, Muncie, USA.
Publikováno v: Cureus [Cureus] 2022 May 15; Vol. 14 (5), pp. e25020. Date of Electronic Publication: 2022 May 15 (Print Publication: 2022).
Zobrazit plný text záznamu
7
Akademický článek
Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.
Autor: Bluff, J. E.1, Menakuru, S. R.1, Cross, S. S.2, Higham, S. E.1, Balasubramanian, S. P.1, Brown, N. J.1, Reed, M. W.1, Staton, C. A.1 c.a.staton@sheffield.ac.uk
Publikováno v: British Journal of Cancer. 8/18/2009, Vol. 101 Issue 4, p666-672. 7p. 1 Color Photograph, 3 Graphs.
Zobrazit plný text záznamu
8
Akademický článek
Angiogenesis in pre-malignant conditions.
Autor: Menakuru, S. R.1, Brown, N. J.1, Staton, C. A.1, Reed, M. W. R.1
Publikováno v: British Journal of Cancer. 12/16/2008, Vol. 99 Issue 12, p1961-1966. 6p. 1 Chart.
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje